Using 68Ga-DOTATOC PET to evaluate gastroenteropancreatic neuroendocrine tumors

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

Observational IRCCS San Raffaele · NCT06155318

This study is testing if a special type of PET scan can help doctors better diagnose gastroenteropancreatic neuroendocrine tumors in adults.

Quick facts

Study typeObservational
Enrollment300 (estimated)
Ages18 Years and up
SexAll
SponsorIRCCS San Raffaele Academic / other
Drugs / interventionsradiation
Locations1 site (Milan)
Trial IDNCT06155318 on ClinicalTrials.gov

What this trial studies

This observational study focuses on patients diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and aims to incorporate 68Ga-DOTATOC PET/CT scans into their diagnostic work-up. The study will assess the effectiveness of this imaging technique, which targets somatostatin receptors commonly found on these tumors, providing high sensitivity and specificity. Patients over 18 years old with a confirmed diagnosis of GEP-NET will be included, while those with contraindications to MRI will be excluded. The goal is to enhance the diagnostic process for GEP-NETs and improve patient management.

Who should consider this trial

Good fit: Ideal candidates are adults over 18 years old with a histological diagnosis of gastroenteropancreatic neuroendocrine tumors.

Not a fit: Patients under 18 years old or those with contraindications to MRI will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more accurate diagnosis and better management of gastroenteropancreatic neuroendocrine tumors.

How similar studies have performed: Previous studies have shown success with similar imaging approaches in diagnosing neuroendocrine tumors, indicating a promising avenue for this study.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with either histological diagnosis of GEP-NET at radiologic imaging and referred to 68Ga-DOTATOC PET;
* Age \> 18 years old;
* Willing to provide a signed informed consent.

Exclusion Criteria:

* Controindications to MR study (i.e. Pacemaker);
* Age\< 18 years old.

Where this trial is running

Milan

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Gastroenteropancreatic Neuroendocrine Tumor
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.